A Phase 1 Open Label, 2 Part, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole

Trial Profile

A Phase 1 Open Label, 2 Part, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Isavuconazole (Primary)
  • Indications Aspergillosis; Candidiasis; Zygomycosis
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 07 Mar 2017 Results assessing the effect of renal impairment and end-stage renal disease (ESRD) on the pharmacokinetics of isavuconazole and the inactive cleavage product (BAL8728) published in the European Journal of Clinical Pharmacology.
    • 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
    • 26 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top